2,2'-Azinobis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt | 30931-67-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸的卤化、磺化、硝化或亚硝化衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2,2'-Azinobis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt
• 英文别名: ABTS Diammonium；azane;(2E)-3-ethyl-2-[(E)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid
• CAS: 30931-67-0
• 化学式: C₁₈H₁₈N₄O₆S₄*2H₃N
• 分子量: 548.689
• InChiKey: MYVPKQQHSXMGHR-ZGWGUCJNSA-N

物化性质

• 熔点：
  >181oC (dec.)
• 溶解度：
  在水中的溶解度50 mg/mL，非常轻微混浊，绿色
• 稳定性/保质期：

  如果按照规格使用和储存，不会发生分解，目前没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.83
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  208
• 氢给体数：
  3
• 氢受体数：
  11

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29342080
• RTECS号：
  DL7002000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name ABTS [=2,2'-Azinobis(3-ethylbenzothiazoline-
6-sulfonic Acid Ammonium Salt)] [for Biochemical
Research]
Portland OR
Synonym 2,2'-Azinobis(3-ethylbenzothiazoline-6-sulfonic Acid
Ammonium Salt)
Chemical Formula C18H24N6O6S4
CAS Number 30931-67-0

---

Section II. Composition and Information on Ingredients
CAS Number Percent (%) TLV/PEL Toxicology Data
Chemical Name
ABTS [=2,2'-Azinobis(3-ethylbenzothiazoline- Min. 98.0 (N) Not available. Not available.
30931-67-0
6-sulfonic Acid Ammonium Salt)] [for Biochemical
Research]

---

Section III. Hazards Identification
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
Acute Health Effects
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
Eye Contact
minutes. COLD water may be used. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. COLD water may
be used.Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Not available.
Auto-Ignition
Flammability May be combustible at high temperature.
Flammable Limits Not available.
Flash Points Not available.
Combustion Products These products are toxic carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), sulfur oxides (SO2, SO3...).
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
ABTS [=2,2'-Azinobis(3-ethylbenzothiazoline-
6-sulfonic Acid Ammonium Salt)] [for Biochemical Research]

---

Section VI. Accidental Release Measures
Spill Cleanup Irritating Material.
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
Instructions
contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
disposal.

---

Section VII. Handling and Storage
IRRITANT. Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in a
Handling and Storage
dry, cool place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection Splash goggles. Lab coat. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Not available.
Exposure Limits

---

Section IX. Physical and Chemical Properties
Physical state @ 20°C Solid. (Crystalline powder. White to slightly Solubility Soluble in cold water.
pale green.)
Not available.
Specific Gravity
Molecular Weight 548.68 Partition Coefficient Not available.
Boiling Point Not available. Vapor Pressure Not applicable.
Melting Point 300°C (572°F) Vapor Density Not available.
Not available. Not available.
Refractive Index Volatility
Not available.
Critical Temperature Not available. Odor
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with oxidizing agents.

---

Section XI. Toxicological Information
RTECS Number DL7002000
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity Data Not available.
CARCINOGENIC EFFECTS : Not available.
Chronic Toxic Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic Effects Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the eye
is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Continued on Next Page
ABTS [=2,2'-Azinobis(3-ethylbenzothiazoline-
6-sulfonic Acid Ammonium Salt)] [for Biochemical Research]

---

Section XII. Ecological Information
Not available.
Ecotoxicity
Environmental Fate Not available.

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification Not a DOT controlled material (United States).
PIN Number Not applicable.
Proper Shipping Name Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification On DSL.
(Canada)
EINECS Number (EEC) 250-396-6
EEC Risk Statements
R36/37/38- Irritating to eyes, respiratory system and skin.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

ABTS（2,2'-联吡啶四硫酸钠二胺盐）是辣根过氧化物酶 (HRP) 的底物。一项针对 HRP 结合物的微 ELISA 技术研究表明，与 5-氨基水杨酸 (5AS)、对苯二胺 (OPD) 和 O-甲基化邻苯二胺 (OT) 等四种底物相比，ABTS 在灵敏度和稳定性方面表现出色，并以其蓝绿色反应产物提供最佳的可视性。ABTS 是一种典型的过氧化物酶底物。

在大规模 XL 培养条件下培养含有活性蛋白的 HRP 阳性转化子后，在 160 小时内实现了与 ABTS 底物相关的活力为每升 55,000 U/L，并收获包含过氧化酶的上清液。当过氧化氢 (H₂O₂) 浓度超过 0.125 mM 时，ABTS 作为底物会导致酶活性显著下降，表明该酶受到 H₂O₂ 的抑制。不同底物的最大反应速率在 31.2 至 125 µM 范围内。

用途

ABTS 是一种适用于 ELISA 步骤的过氧化物酶基质，可产生可溶性的绿色终产物，并可在 405 nm 处使用分光光度计检测。它也是一种用于检测游离氯的光谱试剂和酶免显色底物。

类别

有毒物品

可燃性危险特性

易燃；燃烧时会产生有毒氮氧化物和硫氧化物烟雾

储运特性

通风、低温干燥

灭火剂

干粉、泡沫、沙土、二氧化碳、雾状水

文献信息

• NOVEL PHYSIOLOGICALLY ACTIVE PEPTIDE AND USE THEREOF
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1308509A1

  公开（公告）日：2003-05-07

  The present invention provides a physiologically active peptide, a DNA encoding the peptide, an antibody which recognizes the peptide, and application methods thereof useful in screening and developing a therapeutic agent for diseases which accompany infection and inflammation, diseases which accompany abnormal differentiation and proliferation of smooth muscle cells, diseases which accompany abnormal activation of fibroblasts, diseases which accompany abnormal activation of a synovial tissue, diseases which accompany disorder of pancreatic β cells, diseases which accompany abnormality of osteoblasts or osteoclasts, diseases which accompany abnormal activation of immunocytes, diseases which accompany disorder of a blood vessel, diseases of an eye based on angiogenesis, diseases which accompany neopla, diseases in which linkage to gene regions of a major histocompatibility antigen is confirmed, and the like.

  本发明提供了一种生理活性肽、编码该肽的DNA、识别该肽的抗体及其应用方法，这些方法可用于筛选和开发治疗伴随感染和炎症的疾病、伴随平滑肌细胞异常分化和增殖的疾病、伴随成纤维细胞异常活化的疾病、伴随滑膜组织异常活化的疾病、伴随胰腺β细胞紊乱的疾病、伴随成骨细胞或破骨细胞异常活化的疾病、伴随成纤维细胞异常活化的疾病的治疗剂、伴随滑膜组织异常活化的疾病、伴随胰腺 β 细胞紊乱的疾病、伴随成骨细胞或破骨细胞异常的疾病、伴随免疫细胞异常活化的疾病、伴随血管紊乱的疾病、基于血管生成的眼部疾病、伴随新生儿疾病的疾病、与主要组织相容性抗原的基因区域相关联的疾病等。
• HUMANIZED ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR−8 AND FRAGMENT OF THE ANTIBODY
  申请人：Kyowa Hakko Kogyo Co., Ltd

  公开号：EP1422243A1

  公开（公告）日：2004-05-26

  The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.

  本发明涉及一种抗 FGF-8 的抗体，特别是一种抗 FGF-8 的人源化抗体及其抗体片段，一种编码上述抗体或抗体片段的 DNA 序列，一种包含该 DNA 序列的载体和一种由该载体转化的宿主细胞，一种利用宿主细胞生产上述抗体或抗体片段的工艺，以及一种利用该抗体或抗体片段的癌症治疗剂和诊断剂。
• ANTIBODY TO HUMAN INSULIN-LIKE GROWTH FACTOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1505075A1

  公开（公告）日：2005-02-09

  For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5 x 109 M-1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

  为了有效治疗诸如癌症等有 hIGF 参与的疾病，人们一直希望开发能与 hIGF-I 和 hIGF-II 两种因子强结合并抑制其功能的抗体以及这些抗体的片段。本发明提供的抗体能够特异性地与人类 IGF-I 和 IGF-II 结合，从而抑制人类 IGF-I 和 IGF-II 的功能，并且用生物传感器 BIACORE 测量，其结合活性的结合常数为 5 x 109 M-1 或更高。此外，本发明还提供了诊断、预防和治疗由 hIGF 介导的疾病以及因异常促进 hIGF 生成而显示病理进展的疾病的方法，这些方法都使用了上述抗体。
• RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1676862A1

  公开（公告）日：2006-07-05

  It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions. The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.

  人们需要用于治疗癌症、肢端肥大症和糖尿病并发症等疾病的药剂，其中 IGF 与这些疾病的进展有关。 本发明提供了一种重组抗体或其抗体片段，它能特异性地与人胰岛素样生长因子-I（以下简称 hIGF-I）和人胰岛素样生长因子-II（以下简称 hIGF-II）结合，从而抑制人 IGF-I 和人 IGF-II 的生物活性、产生该抗体或其抗体片段的转化体，产生该抗体或其抗体片段的工艺，以及包含该抗体或其抗体片段作为有效成分的药物。
• PROCESS FOR PRODUCING PROTEIN A-LIKE PROTEIN WITH USE OF BREVIBACILLUS GENUS BACATERIUM
  申请人：Kaneka Corporation

  公开号：EP1767640A1

  公开（公告）日：2007-03-28

  The present invention relates to an efficient and economical process for producing a protein A-like protein. Hosts such as Escherichia coli and Bacillus subtilis have been used in the production of a protein A-like protein using a genetic recombination technique and however, their low productivity has been a big cause of high cost. Thus, it has been desired strongly to immediately establish a technique enabling the inexpensive, large-scale production of a protein A-like protein using recombinant DNA techniques other than Escherichia coli and Bacillus subtilis. The present invention provides a process for producing a protein A-like protein in large amounts, for example, a process comprising allowing a recombinant Brevibacillus genus bacterium to express and secrete the protein in large amounts into a culture solution and separating and collecting the accumulated protein A-like protein from the culture solution.

  本发明涉及一种生产类蛋白 A 的高效而经济的工艺。大肠杆菌和枯草杆菌等宿主已被用于利用基因重组技术生产类蛋白 A，然而，它们的低生产率一直是成本高的一个重要原因。因此，人们强烈希望立即建立一种技术，以便能够利用大肠杆菌和枯草杆菌以外的 DNA 重组技术，廉价、大规模地生产类蛋白 A。本发明提供了一种大量生产蛋白A样蛋白的工艺，例如，该工艺包括让重组的乳杆菌属细菌大量表达和分泌蛋白到培养液中，并从培养液中分离和收集积累的蛋白A样蛋白。